Date: 2017-09-18
Type of information: Opening of new premises
Compound: expansion of Alachua site
Company: Brammer Bio (USA - MA)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism: gene therapy
Disease:
Details:
- • On September 18, 2017, Brammer Bio , a cell and gene therapy contract development and manufacturing organization (CDMO), announced completion of its clinical capacity expansion in Alachua, Florida. This doubles Brammer's early phase manufacturing capacity to support clients' Phase I/II cell and gene therapy clinical trials.
- Brammer's Florida site incorporates equipment and facility design concepts that are setting the standard for early clinical supply, and ultimately commercial scale manufacturing of these advanced therapies. Brammer develops analytics and manufacturing processes for the major viral gene transfer vector systems: Adeno-associated viral, Adenoviral, Herpesviral, Lentiviral, and Retroviral. The company uses a range of production and purification platforms, including adherent and suspension up to 500L scale at its Florida operations for manufacturing therapeutic vectors using mammalian and insect cell host systems. In addition, Brammer has installed a state-of-the-art isolator and integrated fill line for drug product manufacturing in a range of formats.
- Brammer has invested over $50 million in capacity expansions in 2017 to expand their innovative, early clinical manufacturing in Alachua, Florida, and late-stage clinical capacity and commercial-ready manufacturing capabilities in Cambridge, Massachusetts.
- Brammer currently has a team of 300 biopharmaceutical professionals including over 160 based in Florida. The company announced earlier this year the establishment of its Massachusetts facilities for late-stage clinical and commercial production of cell and gene therapy products.
Financial terms:
Latest news:
Is general: Yes
